• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Biogen Idec (NQ:BIIB)

    216.06 -0.57 (-0.26%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Biogen Idec

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    60 61 Next >
    News headline image
    Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB
    From Block & Leviton LLP
    Via GlobeNewswire
    News headline image
    Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Why Biogen (BIIB) Stock Is Up Today
    What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 5.6% in the afternoon session after investors continued to cheer a string of growth sign... 
    Via StockStory
    Topics Artificial Intelligence Earnings
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
    From Pomerantz LLP
    Via GlobeNewswire
    Unusual volume S&P500 stocks in Thursday's session ↗
    Via Chartmill
    News headline image
    Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)
    Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q1 therapeutics earnings season. Over the next ... 
    Via StockStory
    Topics Artificial Intelligence
    MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
    Via Investor Brand Network
    Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
    Via Investor Brand Network
    News headline image
    Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
    Acquisition adds multiple immunology assets to Biogen’s portfolio, including a lead asset poised to enter Phase 1 development 
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
    From BioMedWire
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    3 Overrated Stocks Walking a Fine Line
    The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos... 
    Via StockStory
    News headline image
    BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky
    While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
    Via StockStory
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock. ↗
    Can the drugmaker justify its valuation? 
    Via The Motley Fool
    News headline image
    BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    MarketBeat Week in Review – 05/18 - 05/22 ↗
    Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports 
    Via MarketBeat
    Topics Artificial Intelligence Economy
    News headline image
    Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish ↗
    Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock 
    Via MarketBeat
    News headline image
    Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push ↗
    Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company’s next phase of growth, Adam... 
    Via MarketBeat
    Stay informed with the top movers within the S&P500 index on Thursday. ↗
    Via Chartmill
    News headline image
    Best Healthcare Stocks to Buy in 2026 ↗
    Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies. 
    Via The Motley Fool
    Thursday's session: top gainers and losers in the S&P500 index ↗
    Via Chartmill
    These S&P500 stocks are gapping in today's session ↗
    Via Chartmill
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    60 61 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.